Promising results for mRNA influenza vaccine
FVR – Finnish Vaccine Research has appointed its new Board of Directors
Finnish study investigates possible causal link between shingles vaccination and a reduced risk of dementia
FVR appoints Jenni Vuola as CEO
Vaccine development now and in the future
Adult protection against respiratory infections strengthened – marketing authorisation granted for a new RSV vaccine
FVR grows its core capabilities in vaccine research
Finnish research expertise utilizing national register data produces internationally unique information
FVR joins ImmuDocs doctoral pilot project to increase immunology expertise in Finland
Studying vaccines for pneumococcal disease
Studying vaccines for CMV (cytomegalovirus)
Why partner with FVR – Finnish Vaccine Research in studying vaccines for RSV?
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
Conducting successful clinical trials for influenza vaccines
Moderna announces mRNA-1345, an investigational Respiratory Syncytial Virus (RSV) vaccine, has met primary efficacy endpoints in phase 3 trial in older adults
Pfizer announces positive findings in global maternal immunization trial for its RSV vaccine candidate
Vaccine development thrives – Finland offers unique possibilities
New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above
Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial
